Katharine Foster, James D Anholm, Gary Foster, Suman Thapamagar, Prajan Subedi
{"title":"纳曲酮对高海拔地区睡眠质量和周期性呼吸的影响","authors":"Katharine Foster, James D Anholm, Gary Foster, Suman Thapamagar, Prajan Subedi","doi":"10.1089/ham.2024.0023","DOIUrl":null,"url":null,"abstract":"<p><p>Foster, Katharine, James D. Anholm, Gary Foster, Suman Thapamagar, and Prajan Subedi. Effects of naltrexone on sleep quality and periodic breathing at high altitude. <i>High Alt Med Biol.</i> 00:000-000, 2024. <b><i>Objective:</i></b> This study examined the effects of naltrexone on breathing and sleep at high altitude. Mu-opioid receptor (MOR) agonists have a depressive effect on respiration. Naltrexone is known to block the MOR. We hypothesized that MOR blockade with naltrexone would result in higher nocturnal oxygen saturations, fewer apneas, and improved sleep at high altitude. <b><i>Methods:</i></b> This double-blind, placebo-controlled, crossover study included nine healthy volunteers (four females, five males) aged 27.9 (4.6) (mean [standard deviation]) years. Two overnight trips spaced at least 2 weeks apart took participants from Loma Linda, CA (355 m) to the Barcroft Laboratory, CA (3,810 m) for each arm. Participants ingested either 50 mg naltrexone or matching placebo at bedtime. Sleep metrics were recorded using an ambulatory physiological sleep monitor (APSM). Subjective data were measured with the Groningen Sleep Quality Scale, Stanford Sleepiness Scale, and the 2018 Lake Louise Score (LLS) for acute mountain sickness (AMS). <b><i>Results:</i></b> Mean overnight SpO<sub>2</sub> was lower after taking naltrexone, 81% (6) versus 83% (4) (mean difference 1.9% [2.1, 95% confidence interval or CI = 0.1-3.6, <i>p</i> = 0.040]). The lowest overnight SpO<sub>2</sub> (nadir) was lower on naltrexone 70% (6) versus 74% (4) (dif. 4.6% [4.3], CI = 1.0-8.2, <i>p</i> = 0.020). Total sleep time and total apnea-hypopnea index were unchanged. Subjective sleep quality was significantly worse on naltrexone measured via the Groningen Sleep Quality Scale (<i>p</i> = 0.033) and Stanford Sleepiness Scale (<i>p</i> = 0.038). AMS measured via LLS was significantly worse while taking naltrexone (<i>p</i> = 0.025). <b><i>Conclusion:</i></b> Contrary to our hypothesis, this study demonstrated a significant decrease in nocturnal oxygen saturation, worse sleep quality, and AMS scores. Further characterization of the MOR's effects on sleep and AMS is needed to evaluate potential exacerbating mechanisms for AMS and poor sleep quality at altitude.</p>","PeriodicalId":12975,"journal":{"name":"High altitude medicine & biology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Naltrexone on Sleep Quality and Periodic Breathing at High Altitude.\",\"authors\":\"Katharine Foster, James D Anholm, Gary Foster, Suman Thapamagar, Prajan Subedi\",\"doi\":\"10.1089/ham.2024.0023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Foster, Katharine, James D. Anholm, Gary Foster, Suman Thapamagar, and Prajan Subedi. Effects of naltrexone on sleep quality and periodic breathing at high altitude. <i>High Alt Med Biol.</i> 00:000-000, 2024. <b><i>Objective:</i></b> This study examined the effects of naltrexone on breathing and sleep at high altitude. Mu-opioid receptor (MOR) agonists have a depressive effect on respiration. Naltrexone is known to block the MOR. We hypothesized that MOR blockade with naltrexone would result in higher nocturnal oxygen saturations, fewer apneas, and improved sleep at high altitude. <b><i>Methods:</i></b> This double-blind, placebo-controlled, crossover study included nine healthy volunteers (four females, five males) aged 27.9 (4.6) (mean [standard deviation]) years. Two overnight trips spaced at least 2 weeks apart took participants from Loma Linda, CA (355 m) to the Barcroft Laboratory, CA (3,810 m) for each arm. Participants ingested either 50 mg naltrexone or matching placebo at bedtime. Sleep metrics were recorded using an ambulatory physiological sleep monitor (APSM). Subjective data were measured with the Groningen Sleep Quality Scale, Stanford Sleepiness Scale, and the 2018 Lake Louise Score (LLS) for acute mountain sickness (AMS). <b><i>Results:</i></b> Mean overnight SpO<sub>2</sub> was lower after taking naltrexone, 81% (6) versus 83% (4) (mean difference 1.9% [2.1, 95% confidence interval or CI = 0.1-3.6, <i>p</i> = 0.040]). The lowest overnight SpO<sub>2</sub> (nadir) was lower on naltrexone 70% (6) versus 74% (4) (dif. 4.6% [4.3], CI = 1.0-8.2, <i>p</i> = 0.020). Total sleep time and total apnea-hypopnea index were unchanged. Subjective sleep quality was significantly worse on naltrexone measured via the Groningen Sleep Quality Scale (<i>p</i> = 0.033) and Stanford Sleepiness Scale (<i>p</i> = 0.038). AMS measured via LLS was significantly worse while taking naltrexone (<i>p</i> = 0.025). <b><i>Conclusion:</i></b> Contrary to our hypothesis, this study demonstrated a significant decrease in nocturnal oxygen saturation, worse sleep quality, and AMS scores. Further characterization of the MOR's effects on sleep and AMS is needed to evaluate potential exacerbating mechanisms for AMS and poor sleep quality at altitude.</p>\",\"PeriodicalId\":12975,\"journal\":{\"name\":\"High altitude medicine & biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"High altitude medicine & biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/ham.2024.0023\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOPHYSICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"High altitude medicine & biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ham.2024.0023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
摘要
Foster, Katharine, James D. Anholm, Gary Foster, Suman Thapamagar, and Prajan Subedi.纳曲酮对高海拔地区睡眠质量和周期性呼吸的影响。00:000-000, 2024.目的:本研究探讨了纳曲酮对高海拔地区呼吸和睡眠的影响。缪阿片受体(MOR)激动剂对呼吸有抑制作用。已知纳曲酮能阻断 MOR。我们假设,使用纳曲酮阻断 MOR 会提高夜间血氧饱和度,减少呼吸暂停,并改善高海拔地区的睡眠。研究方法这项双盲、安慰剂对照、交叉研究包括九名健康志愿者(四名女性,五名男性),年龄为 27.9(4.6)(平均值[标准差])岁。每组参与者从加利福尼亚州洛马林达(海拔 355 米)到加利福尼亚州巴克罗夫特实验室(海拔 3810 米)进行了两次隔夜旅行,每次旅行间隔至少 2 周。参与者在睡前服用 50 毫克纳曲酮或相应的安慰剂。使用动态生理睡眠监测仪(APSM)记录睡眠指标。主观数据采用格罗宁根睡眠质量量表、斯坦福嗜睡量表和 2018 年急性登山病(AMS)路易斯湖评分(LLS)进行测量。结果显示服用纳曲酮后的平均过夜SpO2较低,为81%(6人)对83%(4人)(平均差异为1.9% [2.1,95%置信区间或CI = 0.1-3.6,P = 0.040])。纳曲酮的最低夜间 SpO2(最低点)较低,为 70%(6 人)对 74%(4 人)(差异为 4.6% [4.3],CI = 1.0-8.2,P = 0.020)。总睡眠时间和总呼吸暂停-低通气指数保持不变。通过格罗宁根睡眠质量量表(p = 0.033)和斯坦福嗜睡量表(p = 0.038)测量,服用纳曲酮后主观睡眠质量明显降低。通过 LLS 测量的 AMS 在服用纳曲酮后明显降低(p = 0.025)。结论与我们的假设相反,这项研究表明,夜间血氧饱和度明显降低,睡眠质量和急性嗜睡量表评分均有所下降。需要进一步确定 MOR 对睡眠和高山反应的影响,以评估高山反应和睡眠质量差的潜在加剧机制。
Effects of Naltrexone on Sleep Quality and Periodic Breathing at High Altitude.
Foster, Katharine, James D. Anholm, Gary Foster, Suman Thapamagar, and Prajan Subedi. Effects of naltrexone on sleep quality and periodic breathing at high altitude. High Alt Med Biol. 00:000-000, 2024. Objective: This study examined the effects of naltrexone on breathing and sleep at high altitude. Mu-opioid receptor (MOR) agonists have a depressive effect on respiration. Naltrexone is known to block the MOR. We hypothesized that MOR blockade with naltrexone would result in higher nocturnal oxygen saturations, fewer apneas, and improved sleep at high altitude. Methods: This double-blind, placebo-controlled, crossover study included nine healthy volunteers (four females, five males) aged 27.9 (4.6) (mean [standard deviation]) years. Two overnight trips spaced at least 2 weeks apart took participants from Loma Linda, CA (355 m) to the Barcroft Laboratory, CA (3,810 m) for each arm. Participants ingested either 50 mg naltrexone or matching placebo at bedtime. Sleep metrics were recorded using an ambulatory physiological sleep monitor (APSM). Subjective data were measured with the Groningen Sleep Quality Scale, Stanford Sleepiness Scale, and the 2018 Lake Louise Score (LLS) for acute mountain sickness (AMS). Results: Mean overnight SpO2 was lower after taking naltrexone, 81% (6) versus 83% (4) (mean difference 1.9% [2.1, 95% confidence interval or CI = 0.1-3.6, p = 0.040]). The lowest overnight SpO2 (nadir) was lower on naltrexone 70% (6) versus 74% (4) (dif. 4.6% [4.3], CI = 1.0-8.2, p = 0.020). Total sleep time and total apnea-hypopnea index were unchanged. Subjective sleep quality was significantly worse on naltrexone measured via the Groningen Sleep Quality Scale (p = 0.033) and Stanford Sleepiness Scale (p = 0.038). AMS measured via LLS was significantly worse while taking naltrexone (p = 0.025). Conclusion: Contrary to our hypothesis, this study demonstrated a significant decrease in nocturnal oxygen saturation, worse sleep quality, and AMS scores. Further characterization of the MOR's effects on sleep and AMS is needed to evaluate potential exacerbating mechanisms for AMS and poor sleep quality at altitude.
期刊介绍:
High Altitude Medicine & Biology is the only peer-reviewed journal covering the medical and biological issues that impact human life at high altitudes. The Journal delivers critical findings on the impact of high altitude on lung and heart disease, appetite and weight loss, pulmonary and cerebral edema, hypertension, dehydration, infertility, and other diseases. It covers the full spectrum of high altitude life sciences from pathology to human and animal ecology.